Androgenetic Alopecia is under clinical development by Cosmo Pharmaceuticals and currently in Phase III for Androgenic Alopecia. According to GlobalData, Phase III drugs for Androgenic Alopecia does not have sufficient historical data to build an indication benchmark PTSR for Phase III. GlobalData uses proprietary data and analytics to create drugs-specific PTSR and LoA in the Androgenetic Alopecia LoA Report. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Androgenetic Alopecia overview
The drug candidate (CB-0311, Breezula, clascoterone) is under development for the treatment of androgenic alopecia (AGA). The drug candidate is formulated as a solution and is applied topically. It acts by targeting androgen receptor.
Cosmo Pharmaceuticals overview
Cosmo Pharmaceuticals (Cosmo) develops drugs for the treatment of gastrointestinal diseases and dermatology. It develops pharmaceutical products based on its multi-matrix technology. The company’s pipeline products include breezula for androgenetic alopecia; CB-01-35 targets ulcerative colitis and proctitis; CB-01-33 treats bile acid diarrhea; and CB-03-10 targets pancreatic and colon cancers. It also offers eleview which is a submucosal injectable composition for use in gastrointestinal endoscopic procedures. The company’s manufacturing facility is located in Lainate, Milan. Cosmo is headquartered in Dublin, Ireland
For a complete picture of Androgenetic Alopecia’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
